About AKESO Company

Kangfang Biotechnology (Cayman) Co., Ltd. is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody drugs that are affordable to patients around the world. Since its establishment, the company has established an end-to-end comprehensive drug development platform (ACE platform), covering fully integrated drug discovery and development functions, including target verification, antibody drug discovery and development, CMC production process development, and production in line with GMP standards. The company has also successfully developed bispecific antibody drug development technology (Tetrabody technology), which helps the company overcome the three CMC problems encountered in the development and production of bispecific antibodies, including inefficient expression levels, process development barriers, and antibody stability and pharmacogenicity. Up to now, the company has more than 50 research and innovation projects, covering various fields such as oncology, autoimmunity and metabolic diseases. Among them, 10 products are in the commercial or registered phase III clinical trial stage, including 41 self-developed products approved for marketing and 2 products under NMPA marketing review, and 12 novel drug molecules in phase I/II clinical research. 7 are potential first-in-class (first-in-class) or best-in-class (best-in-class) bispecific antibodies. The company hopes to become the world's leading biopharmaceutical company through efficient and innovative research and development, production of the pioneer/best-in-class bispecific antibody, and commercial platform construction.